News

Pillartree Limited, a new subsidiary of Amgen, has struck a deal to acquire Horizon Therapeutics, which markets Uplizna (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD). Last month, Horizon announced that it was in preliminary discussions about a potential sale to three pharmaceutical companies — Amgen,…

People with neuromyelitis optica spectrum disorder (NMOSD) who are diagnosed with at least one non-immune system comorbidity, or simultaneous disease, are at a higher risk of vision loss and paralysis than those without such conditions, a study found. NMOSD patients with these comorbidities also were significantly more likely to…

People with neuromyelitis optica spectrum disorder (NMOSD) and related neurological conditions show reduced brain volume compared with individuals without such diseases, a new study highlights. The results indicate that rates of volume loss in the thalamus — a brain region that helps to relay motor and sensory signals —…

Being positive for or showing high levels of antibodies against the aquaporin-4 (AQP4) protein at diagnosis doesn’t predict worse outcomes for people with neuromyelitis optica spectrum disorder (NMOSD), according to a small study. Plasma exchange therapy was linked with a trend for slower disability progression, although it wasn’t…

People with neuromyelitis optica spectrum disorder (NMOSD) have increased levels in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — of three inflammatory biomarkers, a new study shows. The elevated concentrations of these biomarkers — YKL-40, sCD163, and sCD14 — also…

A chemotherapy regimen was able to treat a woman’s neuromyelitis optica spectrum disorder (NMOSD) which was likely secondary to follicular lymphoma, a type of cancer that begins in cells of the immune system, according to a case report by researchers at King’s College London in the U.K. O-CVP —…

Among people with neuromyelitis optica spectrum disorder (NMOSD) who started treatment with Uplizna (inebilizumab-cdon) in a clinical trial, an early and strong reduction in B-cell counts was associated with a quicker decline in disease activity. This report comes from an analysis of data from the Phase 2/3…

Researchers have identified a rare case of co-existing neuromyelitis optica spectrum disorder (NMOSD) and subacute combined degeneration (SCD) — two distinct disorders marked by nerve damage in the brain or spinal cord. The case highlights the possibility that NMOSD may be the underlying driver of the vitamin B12 deficiency…

Women are more likely to have neuromyelitis optica spectrum disorder (NMOSD) symptoms, or a rebound of symptoms, within three months after delivering a baby, a Chinese study found. Women who didn’t receive immunotherapy during pregnancy and the postpartum period were more than five times as likely to have…

A 67-year-old man developed a rare case of neuromyelitis optica spectrum disorder (NMOSD) after his third dose of the COVID-19 vaccine, a study reports. A review of published literature showed this case adds to 15 other reported cases of post-COVID-19 vaccination NMOSD onset, which appear to show similar clinical…